EUCTR2007-007863-26-GB进行中（未招募）1 期
A multicentre randomized phase II study to assess the safety and resectability in patients with primarily unresectable liver metastases secondary to colorectal cancer receiving 1st line treatment either with mFOLFOX-6 plus bevacizumab or FOLFOXIRI plus bevacizumab - OLIVIA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Histologically confirmed carcinoma of the colon and/or rectum with evidence of liver
- •metastases.
- •- Male and female patients aged greater than or equal to 18 years.
- •- ECOG performance score of 0 or 1.
- •- Written informed consent.
- •- General condition considered feasible for major abdominal surgery after first line treatment.
- •- Unresectability of hepatic metastases at randomisation (at least one of the following criteria):
- •- No upfront R0 / R1 resection of all hepatic lesions possible
- •Note: a patient with bilobar disease suitable for a two-stage
- •resection would still fulfil the inclusion criteria for
- •unresectability.
- •- Less than 30% estimated residual liver after resection
- •- Disease in contact with major vessels of the remnant live
- •(vessels remaining after potential hepatectomy)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •- Evidence of extrahepatic metastatic disease (excluded by FDG-PET).
- •- Evidence of diffuse peritoneal carcinosis or involvement of celiac lymph nodes.
- •- Prior systemic or local treatment of metastatic disease.
- •- Prior adjuvant or neo-adjuvant chemotherapy for primary tumour completed less than 6 months prior to randomisation (Note: in case of synchronous metastatic rectal cancer, chemotherapy/radiotherapy for primary tumour is allowed within 6 months of randomisation).
- •- Treatment with any other investigational agent within 30 days prior to randomisation or participation in another clinical trial while participating in this clinical trial.
- •- Current or recent (within 10 days of randomization) chronic use of aspirin (> 325 mg/day) or clopidrogel (> 75 mg/day).
- •- History or evidence upon physical/neurological examination of CNS disease (unrelated to cancer) (unless adequately treated with standard medical therapy) e.g. uncontrolled seizures.
- •- Past or current history (within the last 2 years prior to randomization) of other malignancies except metastatic colorectal cancer (patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible).
- •- Clinically significant cardiovascular disease, for example CVA, myocardial infarction (less than or equal to 12 months before randomization), unstable angina, New York Heart Association (NYHA) greater than or equal to Class II, congestive heart failure (CHF), arrhythmia requiring medication, or uncontrolled hypertension.
- •- Evidence of bleeding diathesis or coagulopathy.
- •- Known hypersensitivity to any of the study drugs.
- •- Serious, non-healing wound, ulcer or bone fracture.
- •- Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization.
- •- Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications.
- •- Life expectancy less than 3 months.
- •- Inability or unwillingness to comply with the protocol.
- •- Inadequate haematological function: ANC < 1.5x1000000000/L; platelets <100x1000000000/L, Hemoglobin (Hb) < 9 g/dL (may be transfused prior to enrolment).
- •- INR >1.5 within 7 days prior to randomization. aPTT >1.5 x ULN within 7 days prior to randomization.
- •- Liver function: Serum bilirubin > 1.5 x ULN; alkaline phosphatase and transaminases > 5 x ULN (liver metastases).
- •- Serum Creatinine > 1.5 x ULN.
- •- Urine dipstick for proteinuria grater than or equal to 2+. If urine dipstick is greater than or equal to 2+, 24-hour urine must demonstrate less than or equal to 1 g of protein in 24 hours for patient to be eligible.
- •- Pregnancy or lactation.
- •- Positive serum pregnancy test within 7 days of randomization in pre-menopausal women and women < 2 years after the onset of menopause. Note: a negative test has to be reconfirmed by a urine test, should the 7-day window be exceeded.
- •- Fertile w
研究者
相似试验
进行中（未招募）
1 期
A multicentre randomized phase II study to assess the safety and resectability in patients with primarily unresectable liver metastases secondary to colorectal cancer receiving treatment with 5-FU, leucovorin, oxaliplatin and bevacizumab with or without irinotecan as first line treatmentEUCTR2007-007863-26-FRF. Hoffmann-La Roche Ltd80
进行中（未招募）
不适用
A study with bevacizumab in combination with standard of care treatment (mFOLFOX-6 or FOLFOXIRI) to assess the safety and the possibility to surgically remove liver metastasis (spread of the disease to the liver) in patients with inoperable liver metastasis secondary to bowel cancer.EUCTR2007-007863-26-ATF. Hoffmann-La Roche Ltd80
尚未招募
2 期
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged >= 66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT-older AML/high-risk MDS patientsmyelodysplastic syndromes10024324Acute myeloid leukemiaNL-OMON53140HOVO70
进行中（未招募）
1 期
A randomized study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy. ,EUCTR2018-000047-31-NLHOVON Foundation140
已完成
2 期
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) adult AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT- AML/high-risk MDS patients.myelodysplastic syndromes10024324Acute myeloid leukemiaNL-OMON55438HOVO88